|
2007 - Organon officially becomes part of Schering-Plough on November 19.
Akzo receives an offer for the purchase of its wholly owned subsidiary Organon BioSciences N.V. (OBS) from Schering-Plough for EUR 11 billion in cash.
2005 - Organon Research Center in Cambridge, Massachusetts, is formally opened.
2004 - Akzo Nobel announces the integration of Diosynth and Organon into one operating business unit. The new business unit is based in Oss, the Netherlands and Roseland, USA. Investment of EUR 60 million is used to build a state-of-the-art parenteral production facility in Oss, The Netherlands, and a new biotechnology research facility in Cambridge, Massachusetts, United States, is also to be created.
2003 - Pfizer and Akzo Nobel sign a deal for the development of asenapine, an atypical antipsychotic for the treatment of schizophrenia and bipolar disorders.
2002 - Organon establishes a new international office in New Jersey, USA. The Oss site in the Netherlands remains the company’s principal knowledge center for research and development, and production.
2001 - Diosynth acquires Covance Biotechnology Services Inc. and sets up Diosynth RTP, Inc. in North Carolina.
2000 - Diosynth formally opens its state-of-the-art cGMP downstream processing facility and official starts the upstream facility expansion in Oss, The Netherlands.
|
